To include your compound in the COVID-19 Resource Center, submit it here.

Tofacitinib: Phase III data

Top-line data from the double-blind, international Phase III ORAL Standard (1064) trial in 717 patients who had an inadequate response to methotrexate showed that 5 and 10 mg twice-daily oral tofacitinib each met the 3 co-primary endpoints of significantly improving

Read the full 405 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE